文献速递神经肿瘤

医疗差异对哥伦比亚高级别胶质瘤治疗与生存的影响:多中心逆概率加权队列分析

Impact of healthcare disparities on the treatment and survival of patients with high-grade gliomas in Colombia: a multicenter inverse probability-weighted cohort analysis.
PubMed 文献 · J Neurooncol · 2025-08-12

本研究在哥伦比亚波哥大两个学术神经外科中心回顾性纳入2017至2021年手术治疗的113例新诊断高级别胶质瘤成人患者,比较缴费制与补贴制保险人群的辅助治疗可及性与总生存。补贴组术后肿瘤科会诊、化疗和放疗率均显著更低,中位总生存显著更短;逆概率加权调整后,补贴保险、次全切除和未行肿瘤科会诊独立预测更差生存。

要点

  • 补贴保险组术后肿瘤科会诊、化疗和放疗率均显著低于缴费组。
  • 补贴组中位总生存显著短于缴费组(9.8 vs 16.5个月)。
  • 补贴保险、次全切除和未行肿瘤科会诊独立预测更差生存。

核心结论

  • 在哥伦比亚全民医疗体系下,辅助治疗可及性差异可能促成高级别胶质瘤患者的生存差异。
  • 正式保险覆盖广泛存在并不必然确保及时或公平的医疗服务。
  • 性别相关因素可能影响术后肿瘤科照护的可及性。

研究设计与样本

  • 回顾性队列研究,在哥伦比亚波哥大两个学术神经外科中心开展。
  • 纳入2017至2021年接受手术治疗的新诊断高级别胶质瘤成人患者,排除就诊时复发或术后失访者。
  • 共纳入113例患者,其中88例缴费制覆盖、25例补贴制覆盖。
  • 采用倾向评分逆概率治疗加权(IPTW)调整混杂,并应用Cox比例风险及逻辑回归模型。

主要发现

  • 补贴组术后肿瘤科会诊率显著更低(48% vs 84%,p < 0.001)。
  • 补贴组化疗率显著更低(28% vs 68.2%,p < 0.001),放疗率显著更低(8% vs 56.3%,p < 0.001)。
  • 补贴组中位总生存显著更短(9.8 vs 16.5个月,p = 0.006)。
  • IPTW调整后,补贴保险(HR 1.66,95% CI 1.03-2.68,p = 0.035)、次全切除(HR 1.58,95% CI 1.01-2.49,p = 0.045)和未行肿瘤科会诊(HR 5.24,95% CI 1.21-22.63,p = 0.026)独立预测更差生存。
  • 女性(OR 2.59,p = 0.045)和补贴覆盖(OR 8.21,p < 0.001)与未能完成肿瘤科随访相关。

关键数值与推荐

  • 补贴组术后肿瘤科会诊率48% vs 缴费组84%(p < 0.001)。
  • 补贴组化疗率28% vs 缴费组68.2%(p < 0.001),放疗率8% vs 缴费组56.3%(p < 0.001)。
  • 补贴组中位总生存9.8个月 vs 缴费组16.5个月(p = 0.006)。
  • IPTW调整后补贴保险HR 1.66(95% CI 1.03-2.68,p = 0.035),次全切除HR 1.58(95% CI 1.01-2.49,p = 0.045),未行肿瘤科会诊HR 5.24(95% CI 1.21-22.63,p = 0.026)。
  • 女性OR 2.59(p = 0.045)和补贴覆盖OR 8.21(p < 0.001)与未能完成肿瘤科随访相关。

临床怎么用

  • 对高级别胶质瘤患者应关注保险类型以外的实际照护协调与辅助治疗衔接。
  • 术后应确保肿瘤科会诊及时落实,尤其对补贴保险覆盖患者。
  • 应识别并解决影响术后肿瘤科随访的结构性障碍,包括性别相关因素。

局限性

  • 回顾性队列设计,样本量113例,补贴组仅25例。
  • 仅纳入两个学术神经外科中心,可能存在选择偏倚。
  • 未报告分子分型、切除程度详细分类及具体辅助治疗方案等数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Explore the impact of healthcare disparities in patients with high-grade glioma (HGG) in the Colombia's universal healthcare model setting, aiming to assess access to adjuvant treatment and survival outcomes among HGG patients covered under contributory versus subsidized insurance schemes in Bogotá, Colombia. METHODS: A retrospective cohort study was conducted in two academic neurosurgical centers in Bogotá, Colombia, each serving patient populations with a differential distribution by insurance scheme. Adult patients with newly diagnosed high-grade glioma (HGG) who underwent surgical management between 2017 and 2021 were included. Patients with recurrent disease at presentation or lost to follow-up after surgery were excluded. Demographic, clinical, surgical, and treatment data were collected. The primary outcome was overall survival, assessed through medical records and the national death registry. A propensity score model with inverse probability of treatment weighting (IPTW) was used to adjust for confounding. Cox proportional hazards and logistic regression models were applied. RESULTS: A total of 113 patients were included; 88 had contributory coverage and 25 had subsidized coverage. Patients in the subsidized group had significantly lower rates of postoperative medical oncology consultation (48% vs. 84%, 95% p < 0.001), chemotherapy (28% vs. 68.2%, p < 0.001), and radiotherapy (8% vs. 56.3%, p < 0.001). Median overall survival was significantly lower in the subsidized group (9.8 vs. 16.5 months, p = 0.006). After IPTW adjustment, subsidized insurance (HR 1.66, 95% CI 1.03-2.68, p = 0.035), subtotal resection (HR 1.58, 95% CI 1.01-2.49, p = 0.045), and lack of oncology consultation (HR 5.24, 95% CI 1.21-22.63, p = 0.026) were independently predicted worse survival. Female sex (OR 2.59, p = 0.045) and subsidized coverage (OR 8.21, p < 0.001) were associated with failure to complete oncology follow-up. CONCLUSIONS: In the context of a universal healthcare system such as Colombia's, differences in access to adjuvant therapy may contribute to survival disparities among patients with high-grade gliomas. While formal insurance coverage is broadly available, it does not necessarily ensure timely or equitable care delivery. Additionally, our findings suggest that gender-related factors may influence access to postoperative oncology care. Efforts to strengthen care coordination, address structural barriers, and ensure equitable access across insurance types and sexes could help improve outcomes in this population.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Ramirez Ferrer E, Zuluaga-Garcia JP, Alzate JD, et al. Impact of healthcare disparities on the treatment and survival of patients with high-grade gliomas in Colombia: a multicenter inverse probability-weighted cohort analysis. J Neurooncol. 2025. PMID: 40794246. doi:10.1007/s11060-025-05198-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。